女性癫痫患者的管理-专家讲稿.pptxVIP

女性癫痫患者的长程管理 CH/KP/1606/0163 我国癫痫患病率高达7‰ ，约有900万癫痫患者1 其中近一半为女性患者 23%的癫痫病人为育龄期女性（12-50岁）2 中华神经科杂志. 2013; 46(7): 496-499 Joint Epilepsy Council of the UK and Ireland (2011) 女性癫痫概述 女性癫痫患者需要更多关注 中华神经科杂志. 2013; 46(7): 496-499 EMA有关VPA的黑框警告 CEA-ILAE 2015指南更新 女性癫痫患者的药物治疗 女性癫痫患者的管理 EMA有关丙戊酸（VPA）在具生育潜力女性（包括女童，女性青少年，育龄期及怀孕女性）中使用的黑框警告 “ VPA*不应用于女性儿童、女性青少年、具生育潜力的女性以及怀孕的女性，除非其他治疗均无效或不耐受。” 4.4.1 Special warnings Female children/Female adolescents/Women of childbearing potential/Pregnancy: Epilim should not be used in female children, in female adolescents, in women of childbearing potential and pregnant women unless alternative treatments are ineffective or not tolerated because of its high teratogenic potential and risk of developmental disorders in infants exposed in utero to valproate. The benefit and risk should be carefully reconsidered at regular treatment reviews, at puberty and urgently when a woman of childbearing potential treated with Epilim plans a pregnancy or if she becomes pregnant. Women of childbearing potential must use effective contraception during treatment and be informed of the risks associated with the use of Epilim during pregnancy (see section 4.6). The prescriber must ensure that the patient is provided with comprehensive information on the risks alongside relevant materials, such as a patient information booklet, to support her understanding of the risks. In particular the prescriber must ensure the patient understands: • The nature and the magnitude of the risks of exposure during pregnancy, in particular the teratogenic risks and the risks of developmental disorders. • The need to use effective contraception. • The need for regular review of treatment. • The need to rapidly consult her physician if she is thinking of becoming pregnant or there is a possibility of pregnancy. In women planning to become pregnant all efforts should be made to switch to appropriate alternative treatment prior to conception, if possible (see section 4.6).